Colorectal Cancer, Glioma, Hepatocellular Carcinoma, Solid Tumor
Conditions
Brief summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Detailed description
In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be asked to continue to undergo long-term gene safety follow-up.
Interventions
DRUGKD-025 CAR-T cells
Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Sponsors
KAEDI
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18, male & female; 2. Patients with recurrent/refractory NKG2DL+ tumors diagnosis by pathological histology or cytology, focus on the inclusion of patients with hepatocellular carcinoma positive. (If recruit liver cancer patients, patients should with locally advanced or metastatic hepatocellular carcinoma (HCC), Barcelona clinic liver cancer (BCLC) staging system classification for B or C, for B, patients are not suitable for local treatment and/or surgery, or disease progression occurs after surgery and/or local treatment, or declined to surgery and/or local treatment); 3. Patients who fail first-line treatment or are unwilling to receive first-line treatment; 4. Disease progression occurred within 14 days before inclusion (RECIST criteria must be used as a basis for assessment of disease progression). According to RECIST V1.1, patients have at least one measurable lesion. Target lesions located within the field of previous therapeutic irradiation or within the area of local treatment (interventional or ablative treatment) are considered measurable if progress is confirmed; 5. The main organs function normally and meet the following requirements; Blood routine examination shall be in accordance with (no blood transfusion within 14 days) : 1. HB≥90g/L 2. ANC ≥1.5×10\^9/L 3. PLT ≥75×10\^9/L serum biochemicals examination shall be in accordance with: 1. BIL \<1.5 upper normal limit (ULN) 2. ALT and AST\<2.5×ULN; In the case of liver metastasis, ALT and AST\<5×ULN 3. Serum Cr≤1×ULN, endogenous creatinine clearance≥50ml/min(Cockcroft-Gault formula)； 6. ECOG physical condition score: 0-1; 7. Expected survival time ≥3 months; 8. Cardiac function well before inclusion, no myocardial infarction attack occurred within half a year, and hypertension and other coronary heart disease were under control at present; 9. No other uncontrollable benign diseases such as lung, kidney, liver infection before enrollment; 10. Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days of enrollment and voluntarily use an appropriate method of contraception during observation and within 8 weeks after the last administration; men should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and within 8 weeks after the last administration; 11. Patients voluntarily participated in this trial and sign the informed consent form; 12. Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol； 13. CAR-T cells amplify successfully to the expected number.
Exclusion criteria
1. Pregnant or lactating women, pregnancy test positive by blood or urine within 48 hours before immune cell transplantation; 2. Patients who need to be treated with systemic steroid; 3. Under following treatment conditions currently: 1. during the other anti-tumor clinical observation period within 14 days before blood collection; 2. patient has not recovered from acute side effects of the previous treatment; 4. Receive radiotherapy within 4 weeks before enrollment; 5. Patients who received any other cell therapy before; 6. Transfection efficiency of lymphocytes of patients \< 5% in feasibility assessment screening stage, or T cell amplification efficiency \< 5 times； 7. Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis; 8. Patients with severe acute allergic reactions, or the attending doctor believes there is an unpredictable risk; 9. Patients who have received other cell therapies; 10. Other serious conditions that may limit patient's participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) | 90 days post infusion | Incidence of dose-limiting toxicities |
| The occurrence of AEs and SAEs during the study treatment | 0 to 28 days post infusion | An adverse event is any undesirable experience associated with the use of a medical product in a patient |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate(ORR) | 1 year post infusion | Imaging assessment of tumor remission |
| Progression free survival(PFS) | 2 year post infusion | Progress Free Survival after administration |
| Overall survival (OS) | 2 years post infusion | overall survival refers to the period from being included in the test group to death caused by any reason |
Countries
China
Contacts
Primary ContactBaorui Liu, M.D
Backup ContactJie Shen, M.D
Outcome results
None listed